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ABSTRACT 
Introduction: Thienopyridines are a class of antiplatelet drugs widely used in 
cardiovascular disease prevention and treatment. There is recent concern regarding 
the safety of thienopyridines because of possible malignancy risk. Therefore, we 
performed a systematic review and meta-analysis to evaluate the association between 
thienopyridine exposure and malignancy. 
Methods:  We searched MEDLINE and EMBASE in March 2016 for studies which 
evaluated incident cancer and cancer mortality with and without exposure to 
thienopyridines. Relevant studies were identified, data were extracted and analysed 
with random effects meta-analysis. 
Results: A total of 9 studies (6 randomised controlled trials and 3 cohort studies) with 
311,595 participants were included. The cancer event rate during the study period 
with clopidogrel and prasugrel was 1.56%. When compared to standard aspirin or 
placebo, thienopyridines are not significantly associated with cancer mortality and 
event rate OR 1.12 [95% CI 0.80-1.56, n=3] and OR 0.92 [95% CI 0.52-1.64, n=2] 
respectively. Further analyses examining clopidogrel only showed no significant 
association with cancer event rate or malignancy related death. When comparing 
prasugrel to clopidogrel no significant association was noted for cancer event rate OR 
1.10 [95% CI 0.89-1.37, n=2]. Subanalyses according to cancer location showed that 
thienopyridines are not significantly associated with malignancy mortality and/or 
incidence.  
Conclusions: Our results suggest that there is currently insufficient evidence to 
suggest that thienopyridine exposure is associated with an increased risk of cancer 
event rate or mortality. 
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Key points:  
• Cancer-related mortality is not linked to thienopyridines with contemporary data 
• Standardisation of cancer-end points in trials will reduce adjudication bias 
• Cohort studies can be used to supplement trial findings due to longer follow-up 
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1. INTRODUCTION 
Thienopyridines - ticlodipine, clopidogrel and prasugrel – are adenosine 
diphosphate P2Y12 platelet receptor inhibitors that reduce platelet activation. Their 
widespread use in cardiovascular medicine owes much to the pivotal role that platelet 
activation has in the pathophysiology of many cardiovascular diseases such as 
myocardial infarction, stroke and peripheral vascular disease (1). Due to their 
favourable profile, thienopyridines - mainly clopidogrel and recently prasugrel - are 
increasingly used in the treatment and secondary prevention of acute coronary 
syndrome (2–5), cerebrovascular accidents (6–8) and other peripheral vascular disease 
(9,10). Despite their efficacy in reducing major adverse cardiovascular events, 
secondary analyses of two randomised controlled trials raised concerns of a potential 
interplay between increased incidence of cancer and cancer-related death with 
thienopyridines (11,12). 
The Dual Antiplatelet Therapy (DAPT) study of 11,648 patients compared the 
effects of continued thienopyridines versus placebo beyond 12 months in patients who 
underwent PCI (12) reported that at 33 months follow-up the cancer incidence event 
rate was higher in the continued thienopyridine group (2.0% vs 1.6%, p=0.12), whilst 
cancer-related mortality was significantly higher in the continued thienopyridine 
group (0.6% vs 0.3%, p=0.02). However, the latter was not significant once cancer 
prior to enrolment was excluded from the analysis. Conversely, the CHARISMA 
randomized controlled trial in 15,603 patients (13), after adjusting for relevant 
confounders, showed a reduced, though not statistically significant reduction in 
cancer-related mortality with aspirin and clopidogrel [aHR 0.854, 95% CI 0.588-
1.240] at 30 months. Similarly, a retrospective observational cohort study of 
clopidogrel exposure in a cohort of 41,403 newly diagnosed patients with colorectal, 
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breast and prostate cancer influenced cancer-related mortality  reported (after 
adjusting for relevant confounders), no significant differences in cancer related 
mortality for colorectal cancer [aHR 0.98, 95% CI 0.77-1.24, breast cancer [aHR 
1.22, 95% CI 0.90-1.65] or prostate cancer [aHR 1.03 95% CI 0.82-1.28] (14). 
A systematic review by Serebruany et al. studying the incidence of solid 
cancers with antiplatelet therapy reported an association between long exposure to 
antiplatelet therapy and increased risk of new solid cancers and cancer-related 
mortality, though the evidence was not sufficient to alter current practice (15). 
However, the systematic review examined a broad topic, including a limited number 
of heterogeneous studies without a statistical meta-analysis. Moreover, since the 
original review, newer studies have been published increasing the evidence base 
available for analysis. The aim of this report is to perform a systematic review and 
meta-analysis of more contemporary studies and trials to assess whether 
thienopyridines increase the risk of cancer events and malignancy related deaths.   
2. METHODS 
2.1 Search Strategy 
We searched MEDLINE and EMBASE in February 2016 using the broad 
search terms: ((Thienopyridine OR prasugrel OR ticlopidine OR clopidogrel OR 
ticagrelor) AND (Cancer OR carcinoma OR malignancy OR malignant OR neoplasm 
OR tumour OR tumor)). The coverage dates for the former were from 1946 to 
February 2016 and for the latter from 1974 to 29th of February 2016. No language 
restrictions were applied, and translations were not required.  
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2.2 Study selection 
The abstract and titles yielded by the search were screened by two independent 
investigators (RAK, CWW) against the inclusion criteria. Additional studies were 
retrieved by checking the bibliography of included studies and relevant reviews.  The 
full text of the studies that appeared to have met inclusion criteria, were independently 
screened by RAK and CWW at least once, to confirm eligibility for inclusion. The 
results were combined and subsequently reviewed by an experienced reviewer (CSK). 
Disagreements were resolved by consensus after consultation with MAM. 
2.3 Eligibility Criteria 
We included primary studies that reported on malignancy event rate or 
malignancy related mortality after thienopyridine administration. Risk of publication 
bias was minimized by inclusion of conference abstracts or presentations which met 
the inclusion criteria. We excluded studies that evaluated malignancy rates of 
ticlodipine and ticagrelor because the former is no longer clinically used and the latter 
is not strictly a thienopyridine. Additionally, comments, reviews and case reports 
were excluded from the final analysis. When duplicate reports of the same study were 
identified, only the report with the most complete dataset and detailed methodology 
description was included.   
2.4 Data Collection 
Data were extracted independently by two investigators (RAK, CWW) from 
each study into preformatted tables generated in Microsoft Word. Data abstracted 
included information on the year, country, number of participants, participant 
inclusion criteria, evaluated antiplatelets, and cancer outcomes and follow-up. To 
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assess the quality of the included studies we used the Cochrane Collaboration’s Tool 
for assessing risk of bias in randomised controlled trials (RCTs) (16) and the 
Newcastle-Ottawa scale to assess the quality of non-randomised studies (17). For 
studies where outcome data were not available in the primary publication, the 
appendices, other peer-reviewed systematic reviews and Food and Drug 
Administration (FDA) reports were searched for available data. No study 
investigators were contacted for additional information as data were available for all 
included studies. Disagreements were resolved by consensus after consultation with 
MAM. 
2.5 Data Analysis   
On the basis of the availability of data, we synthesized the results using meta-
analysis with quantitative pooling, graphically, or by narrative synthesis. Random and 
fixed effects meta-analyses were performed by the Mantel-Haenszel method for 
dichotomous data using RevMan 5.3 (Nordic Cochrane Centre, København, 
Denmark) in order to estimate pooled risk ratios. Statistical heterogeneity was 
assessed using I2 statistic, The method of pooling has been previously described (18). 
We performed analyses examining cancer event rate and malignancy-related 
mortality. Additionally, we performed sensitivity analysis to detect cancer events rate 
or cancer related mortality with clopidogrel only, also comparing clopidogrel to 
prasugrel.  
 
3. RESULTS 
 A total of 9 studies met the inclusion criteria; 6  randomised controlled trials 
(12,13,19–22) and 3 retrospective cohort studies (14,23,24). The total number of 
participants reached 311,595; varying from 3,479 (23) to 184,871 (24). The process of 
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study selection is presented in Figure I.  Data on study design, participant number, 
inclusion criteria, antiplatelet drugs, the cancer specific follow-up and the outcome 
evalated are presented in Table I. Table II presents a descriptive quality assessment of 
the included studies and Table III the reported cancer outcomes per study.   
 Whilst all studies reported on clopidogrel, only two specifically reported on 
prasugrel (11,20,21), with a wide variety in the outcomes reported by each study; any 
cancer event rate, specific cancer event rate or even cancer related mortality. Cancer 
specific follow-up in RCTs ranged from a minimum of six months to a maximum of 
33 months. Mean weighted follow-up for all studies that reported on follow up was 
9.61 years (12,14,19,21,22,24), but upon exclusion of the cohort studies (14,24) mean 
weighted follow-up was 1.63 years. By contrast, cohort studies had a mean weighted 
follow-up of 10.55 years.  
3.1 Cancer event rate 
 The results and quality assessment of studies are presented in Tables II and III.  
The cancer event rate was  1.56% with clopidogrel  (11–14,19,21,22,24) and 1.56% 
with prasugrel (11,21). Thienopyridine exposure did not associate with increased odds 
of cancer events OR 0.92 [95% CI 0.52-1.64, n=2] (Figure II). This observation was 
retained in a sensitivity analysis with clopidogrel only OR 0.70 [95% CI 0.66-0.75, 
n=1] (Figure III). A further analysis comparing prasugrel to clopidogrel showed no 
significant difference in cancer event rate OR 1.10 [95% CI 0.89-1.37, n=2] (Figure 
IV). All the above relationships were maintained in fixed effects analysis. 
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3.2 Thienopyridines and cancer mortality 
Analysis of studies reporting on cancer mortality indicate that thienopyridine 
treatment versus control or aspirin was not associated with an increased odds of 
mortality OR 1.12 [95% CI 0.80-1.56, n=3] (Figure V), a relationship maintained in 
clopidogrel only sensitivity analysis OR 0.85 [95% CI 0.59-1.24, n=1] (Figure III). 
An analysis comparing prasugrel and aspirin to clopidogrel and aspirin suggested no 
significant differences in the odds of cancer mortality (OR 1.57 [95% CI 0.91-2.71], 
n=1) (Figure IV). When compared to a random effects model, fixed effects meta-
analysis highlighted no significant differences in the odds of cancer mortality with 
thienopyridines in RCTs OR 1.09 [95% CI 0.79, 1.49, n=2], despite a numerically 
different result. 
3.3 Thienopyridine relation to cancer event rate by location 
Data were available for all thienopyridines for lung, colorectal, breast, prostate 
and hepatocellular cancer. In the case of clopidogrel, data were also available for 
pancreatic and haematological cancers. After pooling all studies per cancer site 
thienopyridines and clopidogrel alone were associated with no significant differences 
in cancer event rate (Figure VI, VII) However, in the hepatocellular carcinoma 
subgroup clopidogrel showed a significant decrease in the risk of cancer OR 0.27 
(95% CI 0.09-0.77, n=1).  The comparison of clopidogrel with prasugrel showed no 
significant differences in the odds of site-specific cancer event rates (Figure VIII). 
Fixed effects meta-analysis did not reveal any differences to the random effects meta-
analysis. 
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4. DISCUSSION 
Our analysis suggests there is no evidence of a thienopyridine class effect in 
increasing cancer event rate or malignancy-related mortality when compared to 
standard aspirin or no drug. Subanalyses of cancer mortality and cancer event rates 
also analysed by type of medication showed no cancer signal.  Indeed, our results 
support that the increased cancer mortality with thienopyridines is a chance finding, a 
hypothesis proposed by the DAPT and TRITON TIMI 38 study investigators (12,20). 
Furthermore, our study explores contemporary evidence to examine the 
thienopyridine-cancer hypothesis that has been put forward to explain the findings.  
Our results are based on both RCTs and cohort studies. Our primary analyses 
are largely influenced by two, large, well-designed retrospective cohort studies with 
long-term follow-up of 5 and 12 years respectively. Hicks et al. (14) reported a 
statistically significant reduction in cancer mortality with thienopyridines aOR 0.63 
[95% CI 0.55-0.73], whilst Leader et al. (24) a significant reduction in cancer event 
rate aOR 0.46 [95% CI 0.44-0.49]. Despite the use of multivariate analysis to adjust 
for potential confounders including but not limited to age, gender, smoking status and 
duration of treatment, results from retrospective cohort studies can be influenced by 
unmeasured confounders; limiting subsequent inferences. Our findings are in contrast 
to the DAPT trial findings which showed a statistically significant late increase in 
cancer mortality with prolonged dual antiplatelet therapy of aspirin and 
thienopyridines (0.3% vs 0.6%, p=0.02) (12). It must be noted, however, that in this 
study there was an imbalance of patients with pre-existing, occasionally metastatic, 
cancer between the two arms of the trial after randomisation (12). Additionally, a sub-
analysis excluding cancers diagnosed prior to enrolment exonerated the increased risk 
of cancer mortality.  
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One possible mechanistic explanation for the previous excess of cancer is that 
dual antiplatelet drug regimens increase bleeding risk from pre-existing tumours, 
which in turn may lead to earlier tumour detection on the DAPT group; an 
observation that has been previously reported for anticoagulants and anti-platelets 
(25,26). Moreover, in support of this argument is that patients on anti-platelets have a 
lower rate of advanced stage (IV) colorectal carcinoma compared to the control arm; 
possibly due to detection of existing tumours at an earlier stage (27).   
From a pathophysiological point of view, Serebruany et al. (15) hypothesised 
that antiplatelet medication could be responsible for the increase in cancer incidence 
owing to carcinogenicity of the drug and/or its components. However, this hypothesis 
is not supported by in vivo animal studies which showed that prasugrel and 
clopidogrel were not carcinogenic (11). Regarding the mechanisms underlying cancer 
mortality, Serebruany et al. also suggested that disruption of the platelet-tumour niche 
and the subsequent enhancement of metastatic dissemination might occur. However, 
laboratory evidence suggests that platelets have a pro-metastatic function by 
promoting epithelial to mesenchymal transition, modulating the pre-metastatic niche 
and assisting tumour cells to evade the immune system (28). Therefore, 
administration of thienopyridines should – in theory – reduce the risk of metastasis.  
In favour of this argument, a mouse model of lung metastasis showed that P2Y12 
deficient mice had less tumour burden (29). Therefore, evidence to date does not 
support a pathophysiological link between increased cancer mortality and 
thienopyridine treatment. 
On an individual study level, only DAPT and TRILOGY included a specialist 
oncology adjudication committee to minimise ascertainment bias. The potential effect 
of ascertainment bias on cancer mortality and event rate given the small event rate is 
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important and is highlighted by a recent FDA consensus analysis (11). Moreover, 
sampling bias is an inherent methodological shortfall of the two cohort studies when 
compared to randomised trials. Indeed, the aforementioned weaknesses in individual 
study design could account for the statistical heterogeneity of our results and the 
residual confounding of their individual results. However, sub-group analyses 
including only RCTs for cancer event rate and cancer-mortality with thienopyridines 
(Figures II and V) showed that cohort studies did not alter the results significantly. 
Therefore, our results also benefit from the extended follow-up of the included cohort 
studies.  
Our study is the first meta-analysis to address this contemporary and 
controversial topic using both prospective and retrospective studies. In an era of 
intense pharmacovigilance, our study seeks to clarify concerns raised by DAPT, 
especially when considering that cancer has overtaken cardiac events as the primary 
mortality cause after percutaneous coronary intervention (30,31). Additionally, the 
use of random effects model in our statistical analysis permits inferences of the results 
to the wider population. 
Indeed, as with every meta-analysis, it is inherently limited by the quality of 
the included studies. First, the studies enrolled heterogeneous populations, had 
different study protocols and cancer-event adjudication, and compared different 
duration and combinations of antiplatelet therapies. However, the heterogeneity 
enables examination of different populations which would provide more in the way of 
identifying a phenomenon that affects a particular sub-population. Indeed, our fixed 
effects model analysis did not identify a specific at risk sub-population. Second, the 
safety (cancer event) end-point analyses in trials are observational in nature, 
conducted without a pre-specified hypothesis and the necessary power calculations, 
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predisposing individual studies to Type I error. To minimise these errors, study 
authors grouped various cancers together to increase the event rate and simplify the 
analysis construct; unavoidably limiting the pathophysiological rationale.  However, 
our sensitivity analysis by cancer location yields similar results to the pooled analysis. 
Interestingly, follow-up varied greatly from study to study with trials having 
shorter follow-up at risk of missing late cancers; a high possibility given the late 
cancer signal shown by the DAPT trial (12). However, the study by Hicks et al. with a 
median follow-up of 12.9 years showed an association of reduced cancer mortality 
with clopidogrel use (14). Though the included studies mainly examined clopidogrel, 
DAPT examined clopidogrel and prasugrel and has not published the dichotomised 
data to date. The use of aspirin in the comparison group in early trials could affect the 
results for clopidogrel, but the direction of this effect would likely lead to an 
overshooting of the odds ratio as several studies suggest that aspirin reduces cancer 
event rate and mortality (32–34). Indeed, later trials (CHARISMA, DAPT, 
TRILOGY) have included aspirin in both groups, but the influence of this addition on 
cancer event rate or mortality is unexplored (12,13,21). 
5. CONCLUSIONS 
To our knowledge, this is the first systematic review and meta-analysis to date 
examining whether thienopyridine antiplatelets increase cancer mortality and cancer 
events. We found the cancer event rate was 1.56% for both prasugrel and clopidogrel 
exposed patients. Our study does not support concerns for a class effect of 
thienopyridines in increasing cancer event rate and/or mortality when compared to 
standard aspirin or no drug.  
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Figure I: Flow diagram of study inclusion (35) 
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Table I: Study design, population, antiplatelet drugs evaluated and cancer outcomes 
Study ID Design;Country;Year Total population Participant inclusion criteria Antiplatelet drugs 
evaluated 
Cancer outcomes and 
follow up 
CAPRIE trial 
(22) 
RCT; 
International;1992-
1995. 
19,185 (CLOP 
n=9,599, ASA 
n=9,586). 
Participants had ischaemic stroke, 
myocardial infarction or peripheral 
arterial disease. 
CLOP, ASA. Cancer event rate 
 
Mean follow up 1.63 years 
for lung cancer. 
CHARISMA 
trial (13) 
RCT; International;  
2002-2003. 
 
15,603 (CLOP/ASA 
n=7,802, 
placebo/ASA 
n=7,801). 
Participants were ≥45 years oldand 
had multiple atherothrombotic 
risk factors, coronary disease, 
cerebrovascular disease, or 
peripheral arterial disease. 
CLOP/ASA, placebo/ASA.  Cancer event rate and 
mortality 
 
Up to 30 month follow up 
for cancer events, cancer 
mortality and lung cancer 
events. 
CURE trial 
(19) 
RCT; International; 
1998-2000. 
12,562 (CLOP 
n=6,259, placebo 
n=6,303). 
Participants were >60 years old 
with ECG changes or an elevation 
in the serum level cardiac enzymes 
or markers at study entry. 
CLOP, placebo. Cancer event rate 
 
Follow up 3 monthly until 
the end of the study for 
colorectal cancer and lung 
cancer. 
DAPT  
Study (12) 
RCT; International; 
2009-2011. 
11,648 (12 months 
of dual antiplatelet 
then randomized 
to ASA/Placebo 
n=5,786, dual 
antiplatelet ASA + 
anythienopyridine 
n= 5,862). 
Participants were ≥18 year old with 
dual antiplatelet therapy after DES 
or BMS stent implantation. 
 
Dual antiplatelet therapy 
for 12 months then 
aspirin or continued dual 
antiplatelet. 
Cancer event rate and 
mortality 
 
Follow up from 30-33 
months for all cancers, lung 
cancer, prostate cancer, 
pancreatic cancer, 
colorectal cancer and 
hematologic cancer.  
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Hicks 2015 
(14) 
Retrospective cohort 
study; UK; 1998-
2009. 
41,403 (Colorectal 
Cancer n=10,359, 
Breast Cancer 
n=17,889, Prostate 
Cancer n= 13,155). 
Participants had breast, colorectal 
and prostate cancer diagnosed 
between 1998-2009. 
CLOP. Cancer mortality 
 
Average follow up 5 years 
for colorectal, breast and 
prostate cancer. 
 
Leader 
2015 (24) 
Retrospective cohort 
study; Israel; 2000-
2014. 
184,871 (control 
n=75,624, CLOP 
only n=271, ASA 
only n=64,362, 
dual antiplatelet 
n=15,103). 
Participants were ≥50 year old who 
did not have prasugrel, ticagrelor 
or cancer diagnosis. 
 
CLOP only, ASA only, 
CLOP/ASA. 
 
Cancer event rate 
 
Median follow-up 155 
months for any cancer, 
solid cancers, 
gastrointestinal cancers, 
non-gastrointestinal 
cancers. 
Lee 2015 
(23) 
Retrospective cohort 
study; South Korea; 
Unclear. 
3,479 (no 
antiplatelet 
n=2,891, 
antiplatelet 
n=588). 
Participants had chronic hepatitis B 
and HBV DNA completely 
suppressed with antiviral 
treatment.  
ASA only, CLOP only, 
ASA/CLOP. 
 
Cancer event rate 
 
Not specified follow up for 
hepatocellular carcinoma. 
TRILOGY 
trial (21) 
RCT; International; 
2008-2011. 
9,236. 
 
Participants have unstable angina 
or NSTEMI who had medical 
management. 
 
ASA/CLOP, ASA/prasugrel 
10 mg, ASA/prasugrel 5 
mg. 
Cancer event rate 
 
Median follow up 17 
months for all cancers, lung 
cancer, prostate cancer, 
pancreatic cancer, 
colorectal cancer and 
hematologic cancer. 
TRITON 
TIMI 38 
trial (11, 
RCT; International; 
2004-2007. 
13,608 (Prasugrel 
n=6,813, CLOP 
n=6,795). 
Participants had ACS scheduled for 
PCI. 
 
Prasugrel, CLOP. Cancer event rate and 
mortality 
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20) Follow up between 6-15 
months for all cancers. 
ASA=aspirin, CLOP=clopidogrel, RCT=randomized controlled trial. 
 
 
 
Table II: Quality assessment of included studies using Cochrane Collaboration Tool for randomised controlled trials and the Newcastle Ottawa 
Scale for cohort studies. 
Randomised Controlled Trials1 
Study ID Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Overall Quality 
CAPRIE trial (22) 
Low: computer-
driven 
randomisation and 
concealed 
allocation 
Low: double blind, 
placebo controlled Low 
Low: both groups 
had similar loss to 
followup of 0.22% 
Low High 
CHARISMA trial 
(13) 
Unclear: voice-
response system 
randomisation, but 
no information on 
allocation 
concealment 
Low: double blind, 
placebo controlled Low Unclear Low Average 
CURE trial (19) 
Low: computer-
driven 
randomisation and 
concealed 
Low: double blind, 
placebo controlled 
Low: event adjudication by 
clinicians blinded to 
treatment allocation 
Low: 0.01% loss 
to follow-up in 
both groups 
Low High 
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allocation 
DAPT study (12) 
Low: computer-
driven 
randomisation and 
concealed 
allocation 
Low: double blind, 
placebo controlled 
Low: event adjudication by 
clinicians unaware of 
treatment assignment 
Low: 5.7% loss to 
follow-up in both 
groups 
Low High 
TRILOGY trial (21) Unclear 
Low: double blind, 
active-controlled 
trial 
Unclear 
Low: 0.05% loss 
to follow-up in 
both groups 
Low Average 
TRITON TIMI-38 
trial (11, 20) 
Low: random 
assignment with 
double dummy 
medication 
Low: double blind, 
active-controlled 
trial 
Low:  event adjudication 
by clinicians unaware of 
treatment assignment 
Unclear: no info 
per group but in 
total 0.1% were 
lost to follow-up 
Low High 
Cohort Studies2 
Study ID Selection (max: ****) Comparability (max: **) Outcome (max: ***) Overall Quality 
Leader 2015 
(conference 
abstract) (24) 
*** 
group representative of local population, 
both cohorts from same community, 
ascertainment of exposure using 
prescriptions, unclear if outcome of 
interest present at the beginning though 
** 
Multivariate analysis to 
control for confounding 
factors 
** 
Likely record linkage owing to use 
of ICD-9 coding for outcome 
adjudication, sufficiently long 
follow-up of median 155, but no 
Average 
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very unlikely statement on loss to follow-up 
Lee 2015  
(conference 
abstract) (23) 
* 
Patient group with hepatitis, but 
comparator group from the same 
community. no information on whether 
the outcome of interest was present at 
the beginning neither on how exposure 
was ascertained 
** 
Use of a multivariable Cox 
proportional hazards model 
 
No description on how outcome 
was ascertained, neither on follow-
up period or loss to follow-up. 
Low 
Hicks 2015 (journal 
paper) (14) 
**** 
UK wide population using GP prescription 
data from the UK Clinical Practice 
Research Datalink to ascertain exposure, 
patients with previous diagnosis at start 
of study were excluded 
** 
Use of a multivariable time-
dependent Cox regression 
models to adjust for 
confounders 
*** 
Outcome was ascertained by 
linkage with the National Cancer 
Data Repository and UK Clinical 
Practice Research Datalink 
High 
1: Cochrane Collaboration Tool (16) , 2: Newcastle Ottawa scale (17) 
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Table III: Study results  
Study ID Results 
CAPRIE trial (22) Lung Cancer: Clopidogrel 75 mg 72/9553 vs aspirin 325 mg 74/9546. 
CHARISMA trial 
(13) 
Cancer mortality for clopidogrel/aspirin 75-162 mg vs placebo/aspirin 75-162 mg: aHR: 0.854 (0.588-1.240). Event rate: 51/7,801 vs 
60/7,801. 
Lung cancer for clopidogrel/aspirin aspirin 75-162 mgvs placebo/aspirin 75-162 mg: Event rate 70/7,802 vs 63/7,801.  
CURE trial (19) Colorectal Cancer: Clopidogrel 75 mg/aspirin 75-325 mg 16/6259 vs placebo/aspirin 75-325 mg 8/6303 
Lung Cancer: Clopidogrel 75 mg/aspirin 75-325 mg 12/6259 vs placebo/aspirin 75-325 mg 7/6303 
DAPT study (12) Cancer incidence with thienopyridine continuation/aspirin vs placebo/aspirin: enrolment to randomisation  23/5,862 vs 28/5,786. 
After randomization (12-33 months) 117/5,862 vs 92/5,786. 
Cancer mortality with thienopyridine continuation/aspirin vs placebo/aspirin: 34/5,862 vs 17/5,786. 
Cancer location in related deaths with thienopyridine continuation/aspirin vs placebo/aspirin: Lung cancer: 10/5862 vs 9/5786. 
Prostate cancer: 5/5862 vs 0/5786. Pancreatic: 4/5862 vs 1/5786. Colorectal cancer: 4/5862 vs 0/5786. Hematologic cancer: 2/5862 
vs 1/5786. 
Hicks 2015 (14) Colorectal cancer mortality with clopidogrel use: aHR 0.98 (0.77-1.24). Event rate 72/509 vs 2,649/9,850. 
Breast cancer mortality with clopidogrel use: aHR 1.22 (0.90-1.65). Event rate 46/463 vs 2,172/17,426. 
Prostate cancer mortality with clopidogrel use: aHR 1.03 (0.82-1.28). Event rate 91/850 vs 1,917/12,305. 
Leader 2015 (24) Cancer with aspirin only: aHR 0.54 (0.52-0.56). Event rate 5,692/64,362 vs 8,816/75,624. 
Cancer with clopidogrel only: aHR 0.37 (0.23-0.58). Event rate 18/271 vs 8,816/75,624. 
Cancer with aspirin/clopidogrel: aHR 0.46 (0.44-0.49). Event rate 1,286/15,103 vs 8,816/75,624. 
Lee 2015 (23) Hepatocellular carcinoma and aspirin only: HR 0.18 (0.08-0.39). 
Hepatocellular carcinoma and clopidogrel only: HR 0.11 (0.02-0.81). 
Hepatocellular carcinoma and aspirin/clopidogrel: HR 0.37 (0.15-0.92). 
TRILOGY trial (21) Prasugrel  5-10 mg OD/aspirin <100 mg OD vs clopidogrel 75 mg OD/aspirin <100 mg OD: any cancer 82/4554 vs 78/4551 HR 1.04 
(0.77-1.42), breast cancer 4/4554 vs 2/4551, colorectal cancer 14/4554 vs 6/4551, lung cancer 11/4554 vs 12/4551, prostate cancer 
7/4554 vs 8/4551. 
TRITON TIMI-38 
trial (11, 20) 
New, non-benign neoplasm with prasugrel 10 mg/aspirin 75 mg vs clopidogrel 75 mg/aspirin 75 mg:  94/6741 vs 80/6716.  
Cancer mortality with prasugrel 10 mg/aspirin 75 mg vs clopidogrel 75 mg/aspirin 75 mg:33/6741 vs 21/6716 (RR 1.57 (0.91-2.71)). 
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 Figure II: Cancer event rate with thienopyridine exposure  
 
Figure III: Malignancy related mortality and cancer event rate with clopidogrel exposure. 
 
 
Figure IV: Prasugrel vs clopidogrel in malignancy related mortality and cancer event rate. 
 
 
Figure V: Malignancy related mortality with thienopyridine exposure.
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Figure VI: Thienopyridine exposure and cancer event rate by cancer site 
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Figure VII: Clopidogrel exposure and cancer event rate by cancer location (excluding 
prasugrel/ticagrelor) 
 
Figure VIII: Prasugrel vs clopidogrel exposure and cancer event rate by cancer location 
 
 
 
 
 
